$260,000 grant supports microbiome research to improve melanoma immunotherapy
3 November 2026
Dr. Matthew Anaka at the Cross Cancer Institute and co-investigators Dr. Shokrollah Elahi, Dr. John Walker, and Dr. Dina Kao have secured a $260,000 grant from Cancer Care Alberta to advance the second phase of a two-part clinical trial evaluating fecal microbiota transplantation (FMT) in patients with immunotherapy-resistant melanoma.
Immunotherapy helps the immune system recognize and attack cancer, but some patients do not respond or develop resistance during treatment. The research team is exploring whether the gut microbiome, the community of microorganisms living in the digestive tract, could help restore responsiveness.
Gut bacteria produce signals and metabolites that influence immune activity. FMT transfers a community of microorganisms from donor stool into a recipient’s gut. In this trial, researchers are investigating whether this intervention can establish a microbiome that better supports immune responses against melanoma.
Alongside clinical outcomes, the team will examine changes in gut bacteria and immune activity to understand how FMT may influence treatment response. Elahi’s contribution focuses on the immune mechanisms involved, including changes in T-cell activity, inflammation, and signals that can suppress immune responses against tumours.
The project brings together complementary expertise. Anaka, the principal investigator and oncologist, leads the clinical trial and contributes expertise in melanoma treatment and resistance. Elahi brings immunology expertise, Dr. John Walker strengthens the oncology component, and Dr. Dina Kao contributes gastroenterology and microbiome expertise essential to FMT.
The Cross Cancer Institute provides a coordinated setting that connects cancer care, clinical trial infrastructure, biospecimen collection, and laboratory research. This collaboration enables the team to investigate both whether the intervention benefits patients and the biological changes that may explain those outcomes.
Although FMT remains investigational in this setting, the trial offers an opportunity to explore another approach for patients with limited treatment options. If successful, the findings could inform larger studies and future efforts to use microbiome-based interventions to improve cancer immunotherapy.